Breakthrough Early Stage Cancer Detection System

Free
Message: Verisante Technology Inc. - breakthrough early stage cancer detection

Verisante Technology Inc., will revolutionize how skin and other cancer screening is performed. The technology has been in development for 10 years by some of the world’s leading cancer researchers at the BC Cancer Agency and the University of British Columbia's Faculty of Medicine.

Verisante manufactures a hand held device called the Aura that can scan a skin lesion in seconds, to determine if it is cancerous. The Aura uses an advanced laser scanning system to identify 21 different biochemical markers from the skin and instantly differentiates between malignant (cancerous) and benign (non-cancerous) tissue.

A six year clinical study on 1000 lesions done at Vancouver General Hospital Skin Care Centre produced remarkable results. The preliminary results published in 2008 on 274 lesions demonstrated 100% accuracy, identifying all 34 Melanomas confirmed by biopsy. These results are very impressive when considering accuracy for primary care diagnosis is around 33.8%.

Clinical studies are underway at Vancouver General Hospital for early detection of lung and colon cancer using the same technology.

Verisante’s highly automated detection process will increase survival rates, reduce treatment costs, eliminate unnecessary biopsies and reduce wait times.

Health Canada approval for the Verisante Aura is expected soon.

Regulatory approval forAustralia and the CE Mark for Europe is expected in Q4.

Health Canada approval for the Aura allows other countries who participate in what is known as a mutual recognition process, faster regulatory approval.

Clinical study preparations are currently underway for the US FDA, and discussions will commence immediately following Health Canada Approval.

Here are few statistics on Skin Cancer:

Skin Cancer affects 1 in 5 Americans, 1 in 7 Canadians and represents more than 1/3 of all new Cancers.

Approximately 16,000 people die from combined Melanoma and Non-Melanoma Cancers in Canada & the US each year.

Malignant Melanoma (deadliest form) rates have increased dramatically in many countries more than any other Cancer.

Early detection can result in a 99% survival rate.

http://www.youtube.com/watch?v=_4jgUcxMezM

Why Invest:

-breakthrough in early stage Skin Cancer detection

-clear regulatory pathway to commercialization with significant market potential

-endoscopic device for early detection of lung, colon and cervical cancers in clinical trials

-world-class scientific team and experienced management

-good share structure, company has the necessary capital in place for commercialization

-Health Canada approval expected soon

-Regulatory approval for Europe expected Q4

Direct comparison is Mela Sciences (MELA) - their stock hit $12 without FDA approval.

MELA only deals with melanoma, VRS Aura technology is able to detect all skin cancers.

VRS Core technology detects lung, colon and cervical cancers.

To view media coverage of Verisante click link:

http://verisante.com/news/media/

To view Zacks initiating research on Verisante click link:

http://verisante.com/docs/verisante_zacks.pdf

To view information on the company aired on BTV click link:

http://www.youtube.com/verisante#p/u/2/PHugTxLXQGI

Share
New Message
Please login to post a reply